Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

CJ BIO's BiomeNrichtm POST M005 is the first Akkermansia muciniphila-based ingredient to receive New Dietary Ingredient ...

Corient Private Wealth LLC grew its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 14.7% in the 4th quarter, ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Getinge publishes its Annual Report, including Sustainability Report, for 2024. The report summarizes a year characterized by strong growth, increased customer satisfaction, and successful product ...

Immunovant (NASDAQ:IMVT – Free Report) had its price objective decreased by Bank of America from $38.00 to $33.00 in a ...

Jasmine McCabe-Gossett began noticing mild neuropathy in her hands and feet. It quickly progressed to “one of the most ...